Osang Healthcare Obtains Official Domestic Sales Approval for Rapid Diagnostic PCR Product

[Asia Economy Reporter Hyunseok Yoo] On the 29th, Osang Healthcare, a subsidiary of Osang Jaiel, a KOSDAQ-listed company, announced that its rapid diagnostic kit product, 'GenFinder COVID-19 Fast Real Amp Kit,' has obtained official domestic sales approval.

This product demonstrates 100% accuracy, equivalent to existing PCR products. It is designed to simultaneously detect three genes necessary for COVID-19 testing: RdRp, N, and E. The testing time has been significantly reduced to within one hour.

An Osang Healthcare official stated, "'GenFinder COVID-19 Fast Real Amp Kit' is a product that meets the market's recent demands for both testing accuracy and rapid testing and results," adding, "It is expected to drive innovation in existing COVID-19 testing."

Osang Healthcare, which last year became the first domestic company to receive FDA-EUA certification for a COVID-19 PCR diagnostic kit in the United States, explained that based on its experience selling products to numerous countries worldwide including Europe, the Middle East, Latin America, Asia, and North America, and by reflecting market demands, it has launched a product that dramatically improves testing speed.

This content was produced with the assistance of AI translation services.